GlycoNex
台灣醣聯生技醫藥股份有限公司
GlycoNex is a Taiwan TPEx-listed biotechnology company; its most advanced asset is SPD8 (Phase 3 unblinded; primary endpoint met, Osteoporosis), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| SPD8 | RANKL | Phase 3 unblinded; primary endpoint met | Osteoporosis | Japan | 2026-06-11 | Company disclosure |
| GNX1021 | Branched Lewis B/Y glycan antigen | Phase 1; first patient dosed | Advanced solid tumors | Japan, Taiwan | 2026-08-03 | Company disclosure |
| GNX201-ADC | Tumor-associated carbohydrate antigen | Lead optimization | Solid tumors | — | 2026-03-23 | Company disclosure |
Key events
- GNX1021: Phase 1; first patient dosed
- SPD8: Phase 3 unblinded; primary endpoint met
- GNX201-ADC: Lead optimization
Related Drugnews articles
No related articles in this language.